Neuropeptide VF-associated satiety involves mu and kappa but not delta subtypes of opioid receptors in chicks.
Neuropeptide VF (NPVF) induces satiety through hypothalamic interactions; however, the central mechanism that mediates these effects is poorly understood. Therefore, this study was conducted to explore some possible opioid receptor associated mechanisms of NPVF-induced satiety using chicks as models. Co-injection of NPVF and a mu opioid receptor antagonist (beta-funaltrexamine, FNA) did not have an additive suppressive effect on food intake compared to NPVF and FNA when injected alone. Contrary, co-injection of NPVF and a delta opioid receptor antagonist (ICI-174,864, ICI) caused a greater reduction in food intake than when both were injected alone. Co-injection of NPVF and a kappa opioid receptor antagonist (nor-binaltorphimine, BNI) did not cause an additive suppressive effect on food intake than when the two were injected alone. A reversal of neuropeptide Y and beta-endorphin induction of food intake occurred when NPVF was co-injected. These results support that NPVF-induced satiety is mediated through mu and kappa but not delta subtypes of opioid receptors, and their ligands including neuropeptide Y and beta-endorphin. Thus, NPVF-associated anorexia may be mediated via modulation of the chick's innate opioid-associated orexigenic system.
Cline
Mark A
MA
Department of Biology (6931), Radford University, 100 East Main Street, Radford, VA 24142, USA. mcline@radford.edu
Sliwa
Lindsay N
LN
D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects / Q000502:physiology; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002645:Chickens; D004347:Drug Interactions / Q000502:physiology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D047908:Intracellular Signaling Peptides and Proteins / Q000378:metabolism; D009292:Narcotic Antagonists / Q000494:pharmacology; D009478:Neuropeptide Y / Q000378:metabolism; D009479:Neuropeptides / Q000378:metabolism* / Q000494:pharmacology; D018847:Opioid Peptides / Q000378:metabolism; D000068797:Orexins; D011957:Receptors, Opioid / Q000187:drug effects / Q000378:metabolism*; D017465:Receptors, Opioid, delta / Q000187:drug effects / Q000378:metabolism; D017473:Receptors, Opioid, kappa / Q000187:drug effects / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000187:drug effects / Q000378:metabolism; D012528:Satiety Response / Q000187:drug effects / Q000502:physiology*; D001615:beta-Endorphin / Q000378:metabolism
D047908:Intracellular Signaling Peptides and Proteins; D009292:Narcotic Antagonists; D009478:Neuropeptide Y; D009479:Neuropeptides; D018847:Opioid Peptides; D000068797:Orexins; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; C503959:neuropeptide VF; D001615:beta-Endorphin